AdvaMed Device Submissions Workshop In Brief
New 510(k) paradigm: Level 2 guidance document on 510(k)s is expected to be released by the end of the summer, Office of Device Evaluation Premarket Notification Staff Director Heather Rosecrans tells attendees at AdvaMed's device submissions workshop held June 6-7 in Rockville, Maryland. "We're right at the process of updating the new paradigm, and that's going to go through the GGP [good guidance practices] process. We're going to consider the truthful and accurate...statement in place of the declaration of conformity...with design controls, because there's no end and no beginning and there has been some confusion." Rosecrans highlighted one change for manufacturers submitting 510(k)s: "validation will have to be completed prior to going to market with your device"...
More from Archive
More from Medtech Insight
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.